Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.

Oncologist 2015 Oct 1;20(10):1175-81. Epub 2015 Sep 1.

Mount Sinai Health Systems, New York, New York, USA; Pfizer Oncology, New York, New York, USA; Cone Health Cancer Center, Greensboro, North Carolina, USA; Carolinas Pathology Group, Carolinas HealthCare System, Charlotte, North Carolina, USA; Chao Family Comprehensive Cancer Center, University of California at Irvine School of Medicine, Orange, California, USA; US Oncology Research, Ocala, Florida, USA; Carolinas HealthCare System, Charlotte, North Carolina, USA; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; University of Colorado Cancer Center, Aurora, Colorado, USA.

The recent discovery of relevant biomarkers has reshaped our approach to therapy selection for patients with non-small cell lung cancer. The unprecedented outcomes demonstrated with tyrosine kinase inhibitors in molecularly defined cohorts of patients has underscored the importance of genetic profiling in this disease. Despite published guidelines on biomarker testing, successful tumor genotyping faces significant hurdles at both academic and community-based practices. Oncologists are now faced with interpreting large-scale genomic data from multiple tumor types, possibly making it difficult to stay current with practice standards in lung cancer. In addition, physicians' lack of time, resources, and face-to-face opportunities can interfere with the multidisciplinary approach that is essential to delivery of care. Finally, several challenges exist in optimizing the amount and quality of tissue for molecular testing. Recognizing the importance of biomarker testing, a series of advisory boards were recently convened to address these hurdles and clarify best practices. We reviewed these challenges and established recommendations to help optimize tissue acquisition, processing, and testing within the framework of a multidisciplinary approach.

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591939PMC
October 2015
14 Reads

Publication Analysis

Top Keywords

lung cancer
12
biomarker testing
8
cell lung
8
multidisciplinary approach
8
non-small cell
8
molecular testing
8
oncologists faced
4
testing series
4
practices oncologists
4
series advisory
4
academic community-based
4
community-based practices
4
faced interpreting
4
large-scale genomic
4
recognizing biomarker
4
interpreting large-scale
4
hurdles academic
4
data multiple
4
testing recognizing
4
genomic data
4

Similar Publications